In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and weight loss not meeting patients' expectations.

Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their success in managing blood sugar levels and drastically reducing weight. Between new clinical trial results and a boom in celebrity usage, the popularity of the medications increased drastically over the past two years.

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or stool left in the bowel before an endoscopy or colonoscopy.

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 drugs when it comes to preserving kidney function, a new study finds.

GLP-1 medications—like Ozempic, Wegovy, and Zepbound—can help you shed pounds, but only if taken properly. Don't get caught making these semaglutide slip-ups.

New research suggests GLP-1 medications like Ozempic may help reduce several health risks in addition to treating type 2 diabetes and obesity.